Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: A prospective, randomized study

Basit Öğe Kaydı
dc.authoridBayindir, Yasar/0000-0003-3930-774X
dc.authorwosidBayindir, Yasar/T-1523-2017
dc.contributor.authorBayindir, Y
dc.contributor.authorSonmez, E
dc.contributor.authorAladag, A
dc.contributor.authorBuyukberber, N
dc.date.accessioned2024-08-04T20:13:28Z
dc.date.available2024-08-04T20:13:28Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBrucellosis, a zoonosis with worldwide distribution, is a systemic infection and still an important public health problem in Turkey. The best antimicrobial combination and schedule for the treatment of brucellosis with spondylitis has not yet been clearly determined. In a prospective and randomized study, we compared the efficacy of five antimicrobial regimens for treatment of 102 patients with lumbar brucellar spondylitis. Patients were randomly assigned to receive antimicrobial combination therapy. Twenty patients received streptomycin 1 g/day intramuscularly for 15 days and tetracycline-HCl, 500 mg every 6 h orally for 45 days (ST), 21 patients received streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days (SD), 20 patients received doxycycline 100 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days (DR), 19 patients received ofloxacin, 200 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days (OR), and 22 patients received streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days plus rifampicin 15 mg/kg per day in a single morning dose orally for 45 days (SDR). Initial therapeutic failure occurred in 2 patients (10%) in the ST regimen group, 4 patients (19%) in the SD group, 3 patients (15%) in the DR group and 5 patients (26%) in the OR regimen. In addition, 2 patients (10%) in the DR group and 5 patients (26%) in the OR regimen relapsed during the follow-up period. There was no relapse in any patients in the ST, SD, and SDR groups. The response rates were 90% in the ST and 81% in the SD groups. In contrast, there was a maximum good response (100%) and no relapse in the SDR group. In conclusion, a combination of doxycycline, streptomycin, and rifampicin can be recommended as therapy for brucellar spondylitis and to reduce relapse rates.en_US
dc.identifier.doi10.1179/joc.2003.15.5.466
dc.identifier.endpage471en_US
dc.identifier.issn1120-009X
dc.identifier.issue5en_US
dc.identifier.pmid14598939en_US
dc.identifier.scopus2-s2.0-0142186016en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage466en_US
dc.identifier.urihttps://doi.org/10.1179/joc.2003.15.5.466
dc.identifier.urihttps://hdl.handle.net/11616/93642
dc.identifier.volume15en_US
dc.identifier.wosWOS:000186187400007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherE I F T Srlen_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbrucellar spondylitisen_US
dc.subjectdoxycyclineen_US
dc.subjectstreptomycinen_US
dc.subjectrifampicinen_US
dc.subjectbrucellosisen_US
dc.titleComparison of five antimicrobial regimens for the treatment of brucellar spondylitis: A prospective, randomized studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu